Carsten Denkert

69.2k total citations · 12 hit papers
522 papers, 29.5k citations indexed

About

Carsten Denkert is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Carsten Denkert has authored 522 papers receiving a total of 29.5k indexed citations (citations by other indexed papers that have themselves been cited), including 312 papers in Oncology, 254 papers in Cancer Research and 151 papers in Molecular Biology. Recurrent topics in Carsten Denkert's work include Breast Cancer Treatment Studies (146 papers), HER2/EGFR in Cancer Research (95 papers) and Cancer Genomics and Diagnostics (86 papers). Carsten Denkert is often cited by papers focused on Breast Cancer Treatment Studies (146 papers), HER2/EGFR in Cancer Research (95 papers) and Cancer Genomics and Diagnostics (86 papers). Carsten Denkert collaborates with scholars based in Germany, United States and Belgium. Carsten Denkert's co-authors include Jan Budczies, Manfred Dietel, Sibylle Loibl, Wilko Weichert, Gϋnter von Minckwitz, Balázs Győrffy, Silvia Darb‐Esfahani, András Lánczky, Aron C. Eklund and Qiyuan Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Carsten Denkert

503 papers receiving 29.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

2009 2.2k citations Carsten Denkert, Jan Budczies et al. profile →
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. profile →
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

2009 1.3k citations Carsten Denkert, Sibylle Loibl et al. profile →
Breast cancer

2021 1.0k citations Sibylle Loibl, Carsten Denkert et al. profile →
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

2014 956 citations Sibylle Loibl, Carsten Denkert et al. Annals of Oncology profile →
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

2012 954 citations Jan Budczies, Frederick Klauschen et al. profile →
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies

2016 659 citations Carsten Denkert, Gϋnter von Minckwitz et al. profile →
Clinical relevance of host immunity in breast cancer: from TILs to the clinic

2015 638 citations Carsten Denkert et al. profile →
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

2019 438 citations Sibylle Loibl, Carsten Denkert et al. Annals of Oncology profile →
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

2015 432 citations Carsten Denkert, Holger Eidtmann et al. profile →
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. Annals of Oncology profile →
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Carsten Denkert

Since Specialization

Citations

This map shows the geographic impact of Carsten Denkert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten Denkert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten Denkert more than expected).

Fields of papers citing papers by Carsten Denkert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carsten Denkert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten Denkert. The network helps show where Carsten Denkert may publish in the future.

Co-authorship network of co-authors of Carsten Denkert

This figure shows the co-authorship network connecting the top 25 collaborators of Carsten Denkert. A scholar is included among the top collaborators of Carsten Denkert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carsten Denkert. Carsten Denkert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer 2025 ·Clinical Cancer Research ·(unknown), (unknown), (unknown), (unknown), Inga Hoffmann, Jalid Sehouli, Gerald Niedobitek, Carsten Denkert, Bruno V. Sinn, (unknown), José Carbonell‐Caballero, Alfonso Valencia, Mihnea P. Dragomir, Wolfgang Schmitt, David Horst, Elena Ioana Braicu, Christine Sers, (unknown), Eliane T. Taube	0
2	Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 breakdown → 2024 ·Annals of Oncology ·Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy, Javier Cortés, Rebecca Dent, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Y.H. Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fátima Cardoso, Ying Zhu, Wilbur Pan, Konstantinos Tryfonidis, Peter Schmid	47
3	Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom 2023 ·PubMed ·(unknown), Julia Teply‐Szymanski, (unknown), (unknown), Ramona Erber, Annette Lebeau, Elisabeth Mack, (unknown), Niklas Gremke, (unknown), Thomas Wündisch, Uwe Wagner, Paul Jank, Carsten Denkert	2
4	LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study 2023 ·Annals of Oncology ·Peter Schmid, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Carsten Denkert, Y.H. Park, Rina Hui, (unknown), (unknown), Theodoros Foukakis, (unknown), (unknown), S-A. Im, Fátima Cardoso, Yu Ding, (unknown), Konstantinos Tryfonidis, Joyce O’Shaughnessy	20
5	Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer 2022 ·Cancers ·Jana Ihlow, (unknown), Inga Hoffmann, Philip Bischoff, Bruno V. Sinn, Wolfgang Schmitt, Catarina Alisa Kunze, (unknown), Hagen Kulbe, Elena Ioana Braicu, Jalid Sehouli, Carsten Denkert, David Horst, Eliane T. Taube	8
6	Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups 2021 ·Cancers ·(unknown), Miguel G. Silva, Björn Konukiewitz, (unknown), Katja Steiger, Kathrin Halfter, Jutta Engel, Paul Jank, Nicole Pfarr, Dirk Wilhelm, Sebastian Foersch, Carsten Denkert, Markus Tschurtschenthaler, Wilko Weichert, Moritz Jesinghaus	13
7	Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial 2020 ·Journal of the American Heart Association ·(unknown), Andreas Schneeweiß, Sabine Seiler, Hans Tesch, Marion van Mackelenbergh, Frederik Marmé, Kristina Lübbe, Bruno V. Sinn, Thomas Karn, Elmar Stickeler, Volkmar Müller, Christian Schem, Carsten Denkert, Peter A. Fasching, Valentina Nekljudova, (unknown), Gerd Hasenfuß, Wilhelm Haverkamp, Sibylle Loibl, Stephan von Haehling	26
8	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor 2018 ·Clinical Cancer Research ·Sibylle Loibl, Karsten E. Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit M. Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb‐Esfahani, Volkmar Müller, Annette Staebler, Gϋnter von Minckwitz, Ralf Kronenwett, Carsten Denkert	8
9	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer 2018 ·Molecular Cancer Research ·Ahmed Basudan, Nolan Priedigkeit, Ryan J. Hartmaier, Ethan S. Sokol, Amir Bahreini, Rebecca Watters, M.M. Boisen, Rohit Bhargava, Kurt R. Weiss, Maria Margarete Karsten, Carsten Denkert, Jens‐Uwe Blohmer, José Pablo Leone, Ronald L. Hamilton, Adam Brufsky, Esther Elishaev, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich	24
10	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer 2018 ·Neoplasia ·(unknown), Stephan Wienert, Dan Cacsire Castillo‐Tong, Caroline Kreuzinger, Ignace Vergote, (unknown), Hani Gabra, Charlie Gourley, Ram Ganapathi, (unknown), Jan Budczies, Jalid Sehouli, Ilary Ruscito, Carsten Denkert, Hagen Kulbe, Wolfgang Schmitt, Korinna Jöhrens, Elena Ioana Braicu, Silvia Darb‐Esfahani	20
11	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response 2017 ·Clinical Cancer Research ·Alexander Muckenhuber, Anne Berger, Anna Melissa Schlitter, Katja Steiger, Björn Konukiewitz, Andreas Trumpp, Roland Eils, Jens Werner, Helmut Friess, Iréne Esposito, Günter Klöppel, Güralp O. Ceyhan, Moritz Jesinghaus, Carsten Denkert, Marcus Bahra, Albrecht Stenzinger, Martin R. Sprick, Dirk Jäger, Christoph Springfeld, Wilko Weichert	61
12	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer 2016 ·Clinical Cancer Research ·Sibylle Loibl, Silvia Darb‐Esfahani, Jens Huober, Alexander C. Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit M. Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gϋnter von Minckwitz, Michael Untch, Carsten Denkert	34
13	Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas 2016 ·Cancer Research ·Mika Hilvo, Inês de Santiago, Peddinti Gopalacharyulu, Wolfgang Schmitt, Jan Budczies, Marc Kuhberg, Manfred Dietel, Tero Aittokallio, Florian Markowetz, Carsten Denkert, Jalid Sehouli, Christian Frezza, Silvia Darb‐Esfahani, Elena Ioana Braicu	70
14	Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study 2014 ·Clinical Cancer Research ·Frederick Klauschen, Stephan Wienert, Wolfgang Schmitt, Sibylle Loibl, Bernd Gerber, Jens‐Uwe Blohmer, Jens Huober, Thomas Rüdiger, E Erbstösser, Keyur Mehta, Bianca Lederer, Manfred Dietel, Carsten Denkert, Gϋnter von Minckwitz	78
15	Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer 2014 ·Journal of Clinical Pathology ·Jan Budczies, Moritz von Winterfeld, Frederick Klauschen, (unknown), Jan‐Marcus Daniel, Arne Warth, Volker Endris, Carsten Denkert, Heriberto Pfeiffer, Wilko Weichert, Manfred Dietel, Daniel Wittschieber, Albrecht Stenzinger	13
16	Metabolic Associations of Reduced Proliferation and Oxidative Stress in Advanced Breast Cancer 2012 ·Cancer Research ·Livnat Jerby, Lior Wolf, Carsten Denkert, Gideon Y. Stein, Mika Hilvo, Matej Orešič, Tamar Geiger, Eytan Ruppin	107
17	An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity 2010 ·Cancer Research ·(unknown), Anja Böhnke, Eleonora Leucci, Søren Jensby Nielsen, Irina Lambertz, Stefanie Hammer, (unknown), (unknown), Anja Wolf, Elise Gradhand, Katharina Balschun, Elena Ioana Braicu, Jalid Sehouli, Silvia Darb‐Esfahani, Carsten Denkert, Christoph Thomssen, Steffen Hauptmann, Anders H. Lund, Jean‐Christophe Marine, Frank Bartel	141
18	Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells 2009 ·Cancer Research ·Niels Eckstein, Kati Servan, Barbara Hildebrandt, (unknown), Georg von Jonquières, (unknown), (unknown), Alexandra Hamacher, Matthias U. Kassack, Jan Budczies, Manfred Beier, Manfred Dietel, Brigitte Royer‐Pokora, Carsten Denkert, Hans‐Dieter Royer	134
19	Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo 2008 ·Clinical Cancer Research ·Wilko Weichert, A.-E. Roske, Silvia Niesporek, Aurelia Noske, Ann‐Christin Buckendahl, Manfred Dietel, Volker Gekeler, Markus Boehm, Thomas Beckers, Carsten Denkert	299
20	Mass Spectrometry–Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors 2006 ·Cancer Research ·Carsten Denkert, Jan Budczies, Tobias Kind, Wilko Weichert, (unknown), Jalid Sehouli, Silvia Niesporek, Dominique Könsgen, Manfred Dietel, Oliver Fiehn	304

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact